Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Briacell Therap stock logo
BCTX
Briacell Therap
$7.77
+6.4%
$14.29
$6.00
$294.00
$4.95M1.0799,913 shs49,367 shs
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$2.04
-0.5%
$2.25
$0.40
$3.10
$338.07M2.133.92 million shs1.21 million shs
OptiNose, Inc. stock logo
OPTN
OptiNose
$9.60
$9.57
$4.82
$17.18
$97.22M-0.8863,682 shsN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$4.19
-0.2%
$4.70
$2.83
$11.00
$74.18M1.88474,380 shs411,303 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Briacell Therap stock logo
BCTX
Briacell Therap
-3.95%+11.47%-9.34%-78.65%-93.88%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-0.97%+0.99%-8.89%-18.65%+76.72%
OptiNose, Inc. stock logo
OPTN
OptiNose
0.00%0.00%0.00%0.00%-37.86%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-1.64%-1.18%-4.98%-28.57%+25.94%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Briacell Therap stock logo
BCTX
Briacell Therap
2.8093 of 5 stars
3.55.00.00.02.60.00.6
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
4.1652 of 5 stars
3.51.00.04.72.81.71.3
OptiNose, Inc. stock logo
OPTN
OptiNose
0.7567 of 5 stars
1.00.00.04.20.01.70.6
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
2.632 of 5 stars
3.72.00.00.02.81.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Briacell Therap stock logo
BCTX
Briacell Therap
3.00
Buy$320.004,018.40% Upside
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.00
Buy$5.75181.86% Upside
OptiNose, Inc. stock logo
OPTN
OptiNose
2.00
Hold$9.00-6.25% Downside
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
3.33
Buy$60.001,331.98% Upside

Current Analyst Ratings Breakdown

Latest BCTX, CTMX, UNCY, and OPTN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/31/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$7.00
(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/A($22.02) per shareN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$138.10M2.44$0.36 per share5.66$0.73 per share2.79
OptiNose, Inc. stock logo
OPTN
OptiNose
$81.86M1.19N/AN/A($11.56) per share-0.83
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$680K108.82N/AN/A$0.93 per share4.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Briacell Therap stock logo
BCTX
Briacell Therap
-$4.79M-$83.18N/AN/AN/AN/A-479.97%-182.26%10/27/2025 (Estimated)
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$31.87M$0.563.64N/AN/A34.04%158.70%36.04%11/6/2025 (Estimated)
OptiNose, Inc. stock logo
OPTN
OptiNose
-$35.48M-$3.00N/AN/AN/A-41.16%N/A-27.42%N/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$36.73M-$4.12N/AN/AN/AN/A-243.13%-119.46%11/12/2025 (Estimated)

Latest BCTX, CTMX, UNCY, and OPTN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$0.70-$0.52+$0.18-$0.52N/AN/A
6/13/2025Q3 2025
Briacell Therap stock logo
BCTX
Briacell Therap
-$17.60-$16.40+$1.20-$1.64N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
OptiNose, Inc. stock logo
OPTN
OptiNose
N/AN/AN/AN/AN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Briacell Therap stock logo
BCTX
Briacell Therap
N/A
3.41
3.41
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
4.20
4.20
OptiNose, Inc. stock logo
OPTN
OptiNose
N/A
0.79
0.72
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/A
2.18
2.18

Institutional Ownership

CompanyInstitutional Ownership
Briacell Therap stock logo
BCTX
Briacell Therap
15.42%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
OptiNose, Inc. stock logo
OPTN
OptiNose
85.60%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
40.42%

Insider Ownership

CompanyInsider Ownership
Briacell Therap stock logo
BCTX
Briacell Therap
5.73%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
6.60%
OptiNose, Inc. stock logo
OPTN
OptiNose
2.30%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
10.71%
CompanyEmployeesShares OutstandingFree FloatOptionable
Briacell Therap stock logo
BCTX
Briacell Therap
8680,000639,000No Data
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
170164.91 million154.03 millionOptionable
OptiNose, Inc. stock logo
OPTN
OptiNose
19010.13 million9.83 millionNot Optionable
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
917.66 million15.77 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Briacell Therap stock logo

Briacell Therap NASDAQ:BCTX

$7.77 +0.47 (+6.44%)
Closing price 04:00 PM Eastern
Extended Trading
$7.83 +0.06 (+0.72%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$2.04 -0.01 (-0.49%)
Closing price 04:00 PM Eastern
Extended Trading
$2.05 +0.01 (+0.54%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

OptiNose stock logo

OptiNose NASDAQ:OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Unicycive Therapeutics stock logo

Unicycive Therapeutics NASDAQ:UNCY

$4.19 -0.01 (-0.24%)
Closing price 04:00 PM Eastern
Extended Trading
$4.20 +0.01 (+0.21%)
As of 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.